BANGALORE, June 23 (Reuters) - Acura Pharmaceuticals Inc said its experimental pain drug Acurox would miss its approval date of June 30 as it received a review letter from U.S. health regulators, sending its shares down as much as 36 percent.
BANGALORE, June 23 (Reuters) - Acura Pharmaceuticals Inc said its experimental pain drug Acurox would miss its approval date of June 30 as it received a review letter from U.S. health regulators, sending its shares down as much as 36 percent.
